abrdn Life Sciences Investors (NYSE:HQL) Short Interest Up 22.2% in March
by Renee Jackson · The Cerbat Gemabrdn Life Sciences Investors (NYSE:HQL – Get Free Report) was the target of a significant growth in short interest in March. As of March 31st, there was short interest totaling 39,370 shares, a growth of 22.2% from the March 15th total of 32,205 shares. Based on an average daily volume of 103,796 shares, the short-interest ratio is currently 0.4 days. Approximately 0.2% of the shares of the stock are sold short.
abrdn Life Sciences Investors Price Performance
Shares of HQL traded up $0.08 during midday trading on Thursday, reaching $17.89. The stock had a trading volume of 66,578 shares, compared to its average volume of 125,243. The company’s 50-day moving average is $16.71 and its 200 day moving average is $16.78. abrdn Life Sciences Investors has a 12-month low of $11.72 and a 12-month high of $17.96.
abrdn Life Sciences Investors Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Shareholders of record on Friday, February 20th were paid a $0.56 dividend. This is an increase from abrdn Life Sciences Investors’s previous quarterly dividend of $0.50. This represents a $2.24 annualized dividend and a yield of 12.5%. The ex-dividend date of this dividend was Friday, February 20th.
Institutional Investors Weigh In On abrdn Life Sciences Investors
A number of hedge funds have recently made changes to their positions in HQL. Shaker Financial Services LLC increased its holdings in abrdn Life Sciences Investors by 536.8% during the 3rd quarter. Shaker Financial Services LLC now owns 197,804 shares of the company’s stock valued at $3,068,000 after purchasing an additional 166,742 shares during the period. World Investment Advisors purchased a new stake in abrdn Life Sciences Investors in the 3rd quarter worth approximately $1,440,000. LPL Financial LLC lifted its holdings in abrdn Life Sciences Investors by 20.0% in the 4th quarter. LPL Financial LLC now owns 448,846 shares of the company’s stock worth $7,532,000 after buying an additional 74,787 shares during the period. Wolverine Asset Management LLC grew its position in shares of abrdn Life Sciences Investors by 50.8% in the 3rd quarter. Wolverine Asset Management LLC now owns 215,521 shares of the company’s stock worth $3,343,000 after buying an additional 72,601 shares during the last quarter. Finally, Landscape Capital Management L.L.C. bought a new stake in shares of abrdn Life Sciences Investors in the 4th quarter worth approximately $1,158,000. 32.21% of the stock is currently owned by institutional investors.
About abrdn Life Sciences Investors
abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.
The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.